Protox Therapeutics Inc. announced that it has completed dosing of all four cohorts of patients in its previously announced transrectal study of PRX302 for the treatment of benign prostatic hyperplasia (BPH). The primary objective of this study is to gather safety information regarding the transrectal route of administration for the intraprostatic injection of PRX302. There were no safety issues identified by the Independent Data Monitoring Committee based on data for all patients through at least the first 15 days after dosing.